中华传染病杂志
中華傳染病雜誌
중화전염병잡지
CHINESE JOURNAL OF INFECTIOUS DISEASES
2012年
4期
231-234
,共4页
邱源旺%黄利华%华海涌%牛雪花%吴鹏飞%吴杭源%朱宏英%杨小娟%姚上志%李燚光
邱源旺%黃利華%華海湧%牛雪花%吳鵬飛%吳杭源%硃宏英%楊小娟%姚上誌%李燚光
구원왕%황리화%화해용%우설화%오붕비%오항원%주굉영%양소연%요상지%리일광
晚期血吸虫病%肝炎,乙型%恩替卡韦
晚期血吸蟲病%肝炎,乙型%恩替卡韋
만기혈흡충병%간염,을형%은체잡위
Advanced schistosomiasis%Hepatitis B%Entecavir
目的 观察恩替卡韦(ETV)治疗合并HBV感染的晚期血吸虫病的疗效及安全性.方法 将确诊的60例合并HBV感染的晚期血吸虫病患者分为ETV治疗组30例,大黄治疗组30例(拒绝接受抗病毒治疗),两组在常规治疗基础上分别加用ETV、大黄蛰虫丸治疗,疗程均为52周.比较两组HA、PCⅢ、ⅣC、LN、纤维连接蛋白(FN)等肝纤维化指标及ALT、HBV DNA、Child-Pugh评分结果.分析采用意向性治疗原则(ITT)方法,计量数据和计数数据分别采用t检验和x2检验.结果 治疗52周时,ETV治疗组患者HA、PCⅢ、ⅣC、LN、FN均明显改善,与大黄治疗组比较,差异均有统计学意义(t=3.952、3.765、3.857、3.122、3.735,均P＜0.05)；ETV治疗组部分患者肝组织肝纤维化程度改善,与大黄治疗组比较,差异有统计学意义(x2=11.207,P＜0.05)；ETV治疗组患者ALT、HBV DNA、Child-Pugh评分结果较大黄治疗组明显下降,两组比较,差异均有统计学意义(t=3.287、4.382、3.872,均P＜0.05)；ETV治疗组ALT复常率、HBV DNA在检测水平以下的比率较大黄治疗组明显升高,两组比较,差异有统计学意义(x2=17.376、39.095,均P＜0.05)；且ETV治疗组未出现严重不良反应.结论 ETV治疗合并HBV感染的晚期血吸虫病患者安全有效.
目的 觀察恩替卡韋(ETV)治療閤併HBV感染的晚期血吸蟲病的療效及安全性.方法 將確診的60例閤併HBV感染的晚期血吸蟲病患者分為ETV治療組30例,大黃治療組30例(拒絕接受抗病毒治療),兩組在常規治療基礎上分彆加用ETV、大黃蟄蟲汍治療,療程均為52週.比較兩組HA、PCⅢ、ⅣC、LN、纖維連接蛋白(FN)等肝纖維化指標及ALT、HBV DNA、Child-Pugh評分結果.分析採用意嚮性治療原則(ITT)方法,計量數據和計數數據分彆採用t檢驗和x2檢驗.結果 治療52週時,ETV治療組患者HA、PCⅢ、ⅣC、LN、FN均明顯改善,與大黃治療組比較,差異均有統計學意義(t=3.952、3.765、3.857、3.122、3.735,均P＜0.05)；ETV治療組部分患者肝組織肝纖維化程度改善,與大黃治療組比較,差異有統計學意義(x2=11.207,P＜0.05)；ETV治療組患者ALT、HBV DNA、Child-Pugh評分結果較大黃治療組明顯下降,兩組比較,差異均有統計學意義(t=3.287、4.382、3.872,均P＜0.05)；ETV治療組ALT複常率、HBV DNA在檢測水平以下的比率較大黃治療組明顯升高,兩組比較,差異有統計學意義(x2=17.376、39.095,均P＜0.05)；且ETV治療組未齣現嚴重不良反應.結論 ETV治療閤併HBV感染的晚期血吸蟲病患者安全有效.
목적 관찰은체잡위(ETV)치료합병HBV감염적만기혈흡충병적료효급안전성.방법 장학진적60례합병HBV감염적만기혈흡충병환자분위ETV치료조30례,대황치료조30례(거절접수항병독치료),량조재상규치료기출상분별가용ETV、대황칩충환치료,료정균위52주.비교량조HA、PCⅢ、ⅣC、LN、섬유련접단백(FN)등간섬유화지표급ALT、HBV DNA、Child-Pugh평분결과.분석채용의향성치료원칙(ITT)방법,계량수거화계수수거분별채용t검험화x2검험.결과 치료52주시,ETV치료조환자HA、PCⅢ、ⅣC、LN、FN균명현개선,여대황치료조비교,차이균유통계학의의(t=3.952、3.765、3.857、3.122、3.735,균P＜0.05)；ETV치료조부분환자간조직간섬유화정도개선,여대황치료조비교,차이유통계학의의(x2=11.207,P＜0.05)；ETV치료조환자ALT、HBV DNA、Child-Pugh평분결과교대황치료조명현하강,량조비교,차이균유통계학의의(t=3.287、4.382、3.872,균P＜0.05)；ETV치료조ALT복상솔、HBV DNA재검측수평이하적비솔교대황치료조명현승고,량조비교,차이유통계학의의(x2=17.376、39.095,균P＜0.05)；차ETV치료조미출현엄중불량반응.결론 ETV치료합병HBV감염적만기혈흡충병환자안전유효.
Objective To evaluate the efficacy and safety profiles of enteeavir (ETV) in patients with advanced schistosomiasis and hepatitis B virus (HBV) co-infection.Methods Totally sixty patients with advanced schistosomiasis and HBV co-infection were enrolled in this study.The patients were divided into ETV treatment group (n=30) and rhubarb treatment group who refused to receive antiviral treatment (n=30).The patients were treated with ETV or rhubarb thelepus ball on the basis of routine supportive therapy for 52 weeks.The hepatic fibrosis markers (e.g.hyaluronic acid,type Ⅲ procollagen,type Ⅳ collagen,laminin and fibronectin),alanine transaminase (ALT),HBV DNA,Child-Pugh score between two groups were compared.Intention to treat (ITT) population was used for analysis.The measurement data and the enumeration data were analyzed by t test and x2 test,respectively.Results After 52-week treatment,the hepatic fibrosis markers (hyaluronic acid,type Ⅲ procollagen,type Ⅳ collagen,laminin and fibronectin) were significantly improved in ETV treatment group compared to the rhubarb treatment group (t =3.952,3.765,3.857,3.122 and 3.735,respectively; all P＜0.05),and the fibrosis of liver tissue in ETV treatment group was significantly improved compared with rhubarb treatment group (x2 =11.207,P＜0.05).The ALT level,HBV DNA,Child-Pugh score after 52-weeks treatment in ETV treatment group were statistically reduced compared with rhubarb treatment group (t =3.287,4.382 and 3.872,respectively; all P＜0.05),meanwhile,the ALT normalization rate and HBV DNA undetectable rate were significantly increased in ETV treatment group (x2 =17.376 and 39.095,respectively; both P＜0.05).In addition,no obvious adverse reaction was observed during ETV treatment.Conclusion Entecavir is safe and effective in patients with advanced schistosomiasis and HBV co-infection.
